In November 2013, the U.S. Food and Drug Administration (FDA) halted the marketing of 23andMe's personal genome test. The company was no longer allowed to provide health-related information on the basis of its genome scan. This week, the FDA authorized the marketing of 23andMe's Bloom Syndrome carrier test.
Has the FDA changed its opinion? Well, maybe not. The test that it approved this week is totally different from the one that it halted in 2013.